Evidence map›Paper›PMID 42092818›Full record

SynthesisBMC cancer2026

The impact of advanced glycation end products and their receptors on the development and prognosis of colorectal cancer.

Li-Juan Wang, Xiao-Yu Liu, Can Tan, Zi-Wei Wang, Yong Cheng

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Li-Juan Wang *Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Xiao-Yu Liu *Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Can Tan *Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Zi-Wei WangDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Yong ChengDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. chengyongcq@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study was to analyze whether advanced glycation end products (AGEs) and their receptors had an impact on the development and prognosis of colorectal cancer (CRC).

methodsThis study examined the databases of PubMed, Embase, Cochrane Library databases and CNKI up to 7 February 2024 for cohort studies assessing the association between AGEs and their receptors, including receptor for advanced glycation end products (RAGE) and soluble receptor for advanced glycation end products (sRAGE) on the development and prognosis of CRC.

resultsThe meta-analysis included eight studies with a total of 8,278 participants. It demonstrated that sRAGE expression was significantly lower in CRC patients compared to controls. In contrast, no significant differences were found in the expression levels of RAGE or AGEs between CRC patients and controls. Overall survival was not significantly associated with RAGE expression levels. Subgroup analysis indicated that the inverse association between sRAGE and CRC was significant in the general population but not observed among diabetic patients.

conclusionLow sRAGE expression was associated with an increased risk of CRC development, whereas RAGE and AGEs were not associated with the development and prognosis of CRC.

Indexed as

Colorectal NeoplasmsGlycation End Products, AdvancedReceptor for Advanced Glycation End ProductsBiomarkers, TumorHumansPrognosisBiomarkers, TumorGlycation End Products, AdvancedReceptor for Advanced Glycation End ProductsAdvanced glycation end productsColorectal cancerReceptor for advanced glycation end productsSoluble receptor for advanced glycation end products

Identifiers

PMID42092818
PMCPMC13321642

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.